R&D channel feed

Cerev­el plots first late-stage move as Pfiz­er drug comes through in PhII Parkin­son's tri­al

6 years ago

Uro­Gen steers to­wards its first com­mer­cial drug launch, armed with strong da­ta on lead ther­a­py

6 years ago

Bay Area biotech hauls in $62M to pay the freight on ear­ly-stage CD33/CD3 T cell en­gager

6 years ago

Em­bat­tled AM­AG braces for Oc­to­ber FDA Mak­e­na ad­com, but it need not wor­ry — an­a­lyst

6 years ago
FDA+

Is Re­gen­eron los­ing its R&D mys­tique? An­a­lyst dis­counts big biotech’s run­ner-up de­vel­op­ment strat­e­gy in an in­creas­ing­ly com­modi­tized world

6 years ago

Once tout­ed as Lyri­ca ri­val for di­a­bet­ic nerve pain, Ko­re­an biotech's plas­mid prod­uct im­plodes in PhI­II

6 years ago

FDA puts the brakes on a rare dis­ease biotech’s PhI­II as reg­u­la­tors wait for an up­date — shares crum­ble

6 years ago
FDA+

Akcea’s top 3 C-suite ex­ecs are chopped out as Io­n­is sends in an in­ter­im quar­ter­back from their bench

6 years ago

Here comes the oral GLP-1 drug for di­a­betes — and No­vo Nordisk wants to price Ry­bel­sus 'at a sim­i­lar lev­el as Ozem­pic'

6 years ago
Pharma

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

6 years ago
FDA+

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

6 years ago
Pharma

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

6 years ago
Pharma

Can­cer tri­als aimed at 'sur­ro­gate' tar­gets miss big­ger mark — study

6 years ago

Zol­gens­ma did­n't cause an in­fant death, AveX­is ex­ecs say as they spot­light long-term da­ta

6 years ago
Pharma
Cell/Gene Tx

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

6 years ago
Cell/Gene Tx

Sen­a­tors to FTC: Don't let the big Cel­gene and Al­ler­gan buy­outs hurt R&D and con­sumers

6 years ago
People
Pharma

Young an­ti-ag­ing field takes big step with Mayo Clin­ic senolyt­ics show­case

6 years ago

San Diego cou­ple charged with steal­ing trade se­crets, open­ing Chi­nese biotech as DOJ crack­down con­tin­ues

6 years ago
China

Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

6 years ago

Warts for the win: Aclar­is' lead drug clears piv­otal study

6 years ago

Could psy­che­delics tack­le the obe­si­ty cri­sis? A long­time re­searcher in the field says his lat­est mouse study sug­gests po­ten­tial

6 years ago

Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare neu­ro­mus­cu­lar ail­ment

6 years ago

Seat­tle Ge­net­ics/Astel­las win pri­or­i­ty US re­view for armed an­ti­body aimed at blad­der can­cer

6 years ago
FDA+

Karyopharm lines up $150 mil­lion cash in­jec­tion to back con­tro­ver­sial drug launch

6 years ago
First page Previous page 231232233234235236237 Next page Last page
A service from the Financial Times